Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 11/20 | 0.50 |
| ▸ | NPC1 | O15118 | 10/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.49 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.46 |
| ▸ | FBP1 | P09467 | 1/20 | 0.46 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.46 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 4/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11096876 | 0.82 | TSHR (0.56) | TSHRRAB9ANPC1SMN1; SMN2GRM5 | |
| SCHEMBL19990184 | 0.80 | TSHR (0.57) | TSHRRAB9ANPC1SMN1; SMN2GRM5 | |
| SCHEMBL21146034 | 0.78 | PDCD1 (0.39) | TSHRRAB9ANPC1SMN1; SMN2GRM5 | |
| SCHEMBL4597102 | 0.76 | TSHR (0.47) | TSHRRAB9ANPC1SMN1; SMN2GRM5 | |
| SCHEMBL6700175 | 0.76 | TSHR (0.47) | TSHRRAB9ANPC1SMN1; SMN2GRM5 | |
| SCHEMBL9891915 | 0.76 | TSHR (0.66) | TSHRRAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL10893635 | 0.76 | APOBEC3A (0.53) | TSHRRAB9ANPC1SMN1; SMN2GRM5 | |
| Hydrochloric Acid SCHEMBL6704096 | 0.75 | TSHR (0.46) | TSHRRAB9ANPC1SMN1; SMN2GRM5 | |
| Bromide SCHEMBL6703034 | 0.75 | TSHR (0.46) | TSHRRAB9ANPC1SMN1; SMN2GRM5 | |
| Hydrochloric Acid SCHEMBL10893751 | 0.74 | APOBEC3A (0.52) | TSHRRAB9ANPC1SMN1; SMN2GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7893020-B2 | can be coadministered with antimicrobial agents for treatment of infections caused by drug resistant bacteria; 2-Amino-N-{4-Amino-1-[-3-phenyl-1-(R)-(quinolin-3-ylcarbomoyl)-propylcarbamoyl]-butyl}succinamic acid; 2,5-Diamino-pentanoic acid [3-phenyl-1-(R)-(4-phenyl-thiazol-2-ylcarbamoyl)-propyl]-amide | MPEX PHARMACEUTICALS, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7879795-B2 | can be coadministered with antimicrobial agents for treatment of infections caused by drug resistant bacteria; 2-Amino-N-{4-Amino-1-[-3-phenyl-1-(R)-(quinolin-3-ylcarbomoyl)-propylcarbamoyl]-butyl}succinamic acid; 2,5-Diamino-pentanoic acid [3-phenyl-1-(R)-(4-phenyl-thiazol-2-ylcarbamoyl)-propyl]-amide | MPEX PHARMACEUTICALS, INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-7879795-B2 | can be coadministered with antimicrobial agents for treatment of infections caused by drug resistant bacteria; 2-Amino-N-{4-Amino-1-[-3-phenyl-1-(R)-(quinolin-3-ylcarbomoyl)-propylcarbamoyl]-butyl}succinamic acid; 2,5-Diamino-pentanoic acid [3-phenyl-1-(R)-(4-phenyl-thiazol-2-ylcarbamoyl)-propyl]-amide | MPEX PHARMACEUTICALS, INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20080076741-A1 | ENHANCEMENT OF TIGECYCLINE POTENCY USING EFFLUX PUMP INHIBITORS | REMPEX PHARMACEUTICALS, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20080076741-A1 | ENHANCEMENT OF TIGECYCLINE POTENCY USING EFFLUX PUMP INHIBITORS | REMPEX PHARMACEUTICALS, INC. | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076741-A1 | ENHANCEMENT OF TIGECYCLINE POTENCY USING EFFLUX PUMP INHIBITORS | ABCB1, ABCB11, SLC47A2 | TSHR 2706/4885RAB9A 534/4885NPC1 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.